LONDON |
Tue Dec 11, 2012 6:04am EST
LONDON (Reuters) – A new initial drug that might quarrel drug-resistant strains of a lung illness illness is being tested in South Africa, where a initial studious has been enrolled into a mid-stage clinical trial.
AstraZeneca, that grown a medicine famous as AZD5847, is operative with a U.S. National Institute of Allergy and Infectious Diseases and Case Western Reserve University School of Medicine on a Phase IIa clinical study.
Scientists have found an shocking series of cases of TB that are resistant to many of a many absolute existent antibiotic drugs, underlining a need for new treatments.
AstraZeneca’s new drug is still several years from reaching a market. Even if it works in a trial, serve tests will still be indispensable before it is authorized for use.
The British drugmaker pronounced on Tuesday it designed to exam AZD5847 in serve clinical trials as partial of one or some-more next-generation multiple therapies opposite TB.
(Reporting by Ben Hirschler; Editing by Helen Massy-Beresford)
Source: Health Medicine Network